Plavix

(clopidogrel)

ApprovedSmall molecule

Clopidogrel is a blood thinner that helps prevent blood clots from forming, which is used to reduce the risk of heart attacks and strokes in people with heart disease or who have recently had a stent placed in their arteries.[2] Plavix is currently approved and in use across 58 indications[4].[1]

Plavix is one of 739 small molecule programs targeting Cerebral Amyloid Angiopathy. It is currently in Approved.

Indications

482

Total Trials

Active Trials

738

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Cerebral Amyloid AngiopathyActive, not recruiting

Coronary Artery DiseaseCompleted

Metabolic SyndromeCompleted

Systemic Lupus ErythematosusApproved

Cardiovascular DiseaseApproved

Endothelial DysfunctionActive, not recruiting

Renal Artery StenosisCompleted

Cardiac ArrestActive, not recruiting

Mitral RegurgitationActive, not recruiting

Cerebral Small Vessel DiseaseActive, not recruiting

Cerebral Amyloid AngiopathyPreclinical

Active, not recruiting

Coronary Artery DiseaseApproved

Completed

Metabolic SyndromeApproved

Completed

Systemic Lupus ErythematosusApproved

Approved

Cardiovascular DiseaseApproved

Approved

Endothelial DysfunctionApproved

Active, not recruiting

Renal Artery StenosisApproved

Completed

Cardiac ArrestApproved

Active, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

Cerebral Small Vessel DiseaseApproved

Active, not recruiting

Showing 10 of 55 indications

Competition

Competitive Landscape

169 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

3 2

Uloric

Takeda

Preclinical

2 3

Sovaldi

Gilead

Preclinical

1 4

Glucotrol

Pfizer

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Activase

Flomax

PROCRIT

1 10

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalRecruiting

Percutaneous Coronary Intervention

NCT06228456

Q2 2028

Active, not recruiting

Acute Myocardial Infarction

NCT06454045

Q4 2028

Recruiting

Atherosclerosis

NCT04847752

Q1 2029

Phase 3Recruiting

Heart Transplantation

NCT04770012

Clinical

Trials by Indication[1]

Clopidogrel31 trials

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT01826175

Ticagrelor vs. Clopidogrel in Post PCI Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT05858918·476 enrolled

Safety Study of APD-791 With Aspirin and/or Clopidogrel

Terminated· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 1·NCT02034292·16 enrolled

Show 28 more trials

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT03289520·877 enrolled

75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00140465·60 enrolled

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

Completed·UUniversity of Florida·Phase 4·NCT03437044·40 enrolled

Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT02560688·22 enrolled

Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI

Unknown status·SSheba Medical Center·Phase 3·NCT00889044·30 enrolled

Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel

Completed·UUniversity Hospital Tuebingen·Phase 2/3·NCT00163267·80 enrolled

Bleeding Time Study With AZD6482, Clopidogrel and ASA

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00853450·28 enrolled

Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT01663038·60 enrolled

The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man

Completed·MMedical University of Vienna·Phase 2·NCT02120092·89 enrolled

Pilot Study on the Effect of High Clopidogrel Maintenance Dosing

Completed·SScripps Health··NCT01118793·41 enrolled

Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial

Completed·IIntermountain Health Care, Inc.·Phase 4·NCT00343876·100 enrolled

Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI

Completed·LLene Holmvang·Phase 4·NCT01135667·106 enrolled

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02925923·100 enrolled

COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS

Unknown status·SShenyang Northern Hospital·Phase 4·NCT02578537·60 enrolled

Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.

Completed·UUllevaal University Hospital·Phase 4·NCT00222261·1,001 enrolled

To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects

Completed· Astellas logo

Astellas·Phase 1·NCT01409616·100 enrolled

A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01603342·18 enrolled

Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT01123824·40 enrolled

Hip-Fracture Surgery on Patients in Clopidogrel Therapy

Completed·HHvidovre University Hospital··NCT02391883·356 enrolled

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT01014624·56 enrolled

Clopidogrel Pharmacogenetics (PGX) Bench to Bedside

Completed·UUniversity of Maryland, Baltimore·N/A·NCT01341600·18 enrolled

Clopidogrel Bioequivalence Study in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02185534·144 enrolled

Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding

Completed·—·Phase 4·NCT01806090·216 enrolled

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

Completed· Sanofi logo

Sanofi·Phase 3·NCT00833703·49 enrolled

CASTLE (Clopidogrel And Serum Troponin Level Elevation)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00716924·155 enrolled

The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance

Completed·—·Phase 3·NCT01032668·192 enrolled

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Completed· Takeda logo

Takeda·Phase 1·NCT00942175·160 enrolled

VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel

Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 4·NCT01684813·65 enrolled

Acute Coronary Syndrome17 trials

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT02052635·34 enrolled

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Completed·LLMU Klinikum·Phase 4·NCT01959451·2,600 enrolled

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT03062462·80 enrolled

Show 14 more trials

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00391872·18,624 enrolled

Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome

Terminated·YYonsei University·Phase 4·NCT02037412·148 enrolled

Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome

Unknown status·—·Phase 4·NCT02446730·1,400 enrolled

Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01294462·801 enrolled

Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT01626534·125 enrolled

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00684203·120 enrolled

PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants

Completed·—·Phase 3·NCT01641510·70 enrolled

Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT01107899·29 enrolled

Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome

Unknown status·GGennaro Sardella·Phase 3·NCT01778842·68 enrolled

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01603082·343 enrolled

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00830960·720 enrolled

Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome

Completed·UUniversity of Cologne·Phase 3·NCT01774838·49 enrolled

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00699998·9,326 enrolled

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Completed·TThorax Centrum Twente··NCT03197298·2,062 enrolled

Stroke9 trials

Secondary Prevention of Small Subcortical Strokes Trial

Completed·UUniversity of British Columbia·Phase 3·NCT00059306·3,020 enrolled

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

Completed·NNorthwestern University·Phase 2/3·NCT01586975·93 enrolled

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591351·870 enrolled

Show 6 more trials

The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients

Completed·NNational Cerebral and Cardiovascular Center, Japan··NCT02711410·518 enrolled

Cilostazol and Aspirin in Stroke and TIA

Completed·IIncheon St.Mary's Hospital·Phase 4·NCT06522113·378 enrolled

Cilostazol Stroke Prevention Study for Antiplatelet Combination

Completed·JJapan Cardiovascular Research Foundation·Phase 4·NCT01995370·1,884 enrolled

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

Unknown status·UUniversity of Zurich·Phase 3·NCT03961334·620 enrolled

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03766581·2,366 enrolled

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00153062·20,332 enrolled

Coronary Artery Disease6 trials

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT02889549·60 enrolled

Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 4·NCT01830491·162 enrolled

An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01118325·146 enrolled

Show 3 more trials

Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.

Withdrawn·NNeil Kleiman, MD·Phase 4·NCT01011257

Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan

Completed·TTakeshi Morimoto·Phase 4·NCT01069302·106 enrolled

Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01107912·155 enrolled

Platelet Reactivity6 trials

Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)

Completed·TTaipei City Hospital··NCT03190005·35 enrolled

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00910299·423 enrolled

Genotype and Platelet Reactivity in Patients on Hemodialysis

Unknown status·KKyunghee University Medical Center·Phase 3·NCT02394145·20 enrolled

Show 3 more trials

Platelet Reactivity in Stent Thrombosis Patients

Completed·SSt. Antonius Hospital·Phase 4·NCT01012544·187 enrolled

Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial

Completed·GGennaro Sardella·Phase 3·NCT01465828·30 enrolled

Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

Withdrawn·NNanjing First Hospital, Nanjing Medical University·Phase 3·NCT03078465

72 more indications

Antiplatelet6 trials

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)

Completed·SSeoul National University Hospital·Phase 4·NCT02044250·5,530 enrolled

A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01864005·60 enrolled

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

Completed·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT02217501·159 enrolled

Show 3 more trials

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

Completed·EECRI bv·Phase 3·NCT02833948·231 enrolled

P3AMI Antiplatelet Trial

Completed·TThe Royal Wolverhampton Hospitals NHS Trust·Phase 4·NCT02376283·87 enrolled

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

Completed·—·Phase 1·NCT04822363·112 enrolled

Myocardial Infarction6 trials

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

Completed·TThe TIMI Study Group·Phase 2·NCT01235351·335 enrolled

Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction

Unknown status·GGyeongsang National University Hospital·Phase 4·NCT02224534·326 enrolled

Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)

Completed·UUniversity of Patras·Phase 3·NCT01338909·35 enrolled

Show 3 more trials

Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed·—··NCT03613857·1,022 enrolled

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

Withdrawn·RRegion Skane·Phase 3·NCT04069234

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00976092·548 enrolled

Percutaneous Coronary Intervention5 trials

Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention

Completed·—·Phase 3·NCT01609647·76 enrolled

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

Completed·KKaiser Franz Josef Hospital·Phase 3·NCT01515345·1,008 enrolled

Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention

Completed·PPeking Union Medical College Hospital·Phase 4·NCT02748330·40 enrolled

Show 2 more trials

STEEL Percutaneous Coronary Intervention

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT02327624·180 enrolled

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Recruiting·UUniversity of Florida·Phase 4·NCT06228456·50 enrolled

Antiplatelet Therapy5 trials

Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 4·NCT00728156·90 enrolled

Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial

Completed·SShenyang Northern Hospital·Phase 4·NCT03431142·7,758 enrolled

Antiplatelet Therapy in HIV

Completed·NNYU Langone Health·Phase 2·NCT02559414·55 enrolled

Show 2 more trials

Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy

Unknown status·IImam Abdulrahman Bin Faisal University·Phase 4·NCT01823185·1,500 enrolled

Tailored Antiplatelet Therapy Following PCI

Completed·MMayo Clinic·Phase 4·NCT01742117·5,276 enrolled

Atrial Fibrillation4 trials

Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation

Completed·UUMC Utrecht·Phase 2·NCT02565693·101 enrolled

Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk

Unknown status·—·Phase 3·NCT02960126·1,500 enrolled

Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI

Unknown status·LLudwig-Maximilians - University of Munich·Phase 4·NCT04981041·2,334 enrolled

Show 1 more trial

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01830543·2,124 enrolled

Interaction4 trials

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

Completed·AAkcea Therapeutics·Phase 1·NCT03392051·18 enrolled

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.

Completed·AAscopharm Groupe Novasco·N/A·NCT01175200·82 enrolled

Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT01129388·72 enrolled

Show 1 more trial

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT01129427·66 enrolled

Coronary Artery Bypass4 trials

Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass

Unknown status·YYonsei University·Phase 4·NCT05166538·204 enrolled

Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting

Completed·UUniversity of Zagreb·Phase 4·NCT01159639·200 enrolled

A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting

Completed·—·Phase 4·NCT02330640·137 enrolled

Show 1 more trial

Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study

Completed·HHamilton Health Sciences Corporation·Phase 3·NCT00330772·150 enrolled

Ischemic stroke4 trials

Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

Completed·DDexa Medica Group·Phase 3·NCT01790997·126 enrolled

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke

Completed·KKafrelsheikh University·Phase 3·NCT06120725·580 enrolled

Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization

Unknown status·MMikhail Zykov·Phase 4·NCT06102720·200 enrolled

Show 1 more trial

Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke

Completed·—··NCT01955642·91 enrolled

Antithrombotic3 trials

Resistance to Antithrombotic Therapy

Completed·MMedical University of Vienna·N/A·NCT00858715·46 enrolled

Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI

Completed·CCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec·Phase 4·NCT02640794·222 enrolled

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Recruiting·MMedical University of Gdansk·Phase 4·NCT04695106·2,230 enrolled

Dual Antiplatelet Therapy3 trials

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

Unknown status·BBloodworks·Phase 1/2·NCT03787927·60 enrolled

Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease

Completed·—·Phase 2·NCT04824911·376 enrolled

Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation

Completed·YYonsei University·Phase 4·NCT01192724·630 enrolled

Peripheral Artery Disease3 trials

Residual Platelet Activity In Advanced Peripheral Artery Disease

Unknown status·UUniversity of Roma La Sapienza·Phase 4·NCT01627431·410 enrolled

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT02121288

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01732822·13,885 enrolled

Acute Myocardial Infarction3 trials

Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction

Completed·UUniversity of Zagreb·Phase 4·NCT04369534·120 enrolled

Evaluation of Platelet Aggregability in Patients With Previous Acute Myocardial Infarction or Concomitant Lower Extremity Peripheral Artery Disease

Active, not recruiting·UUniversity of Sao Paulo··NCT06454045·100 enrolled

Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction

Completed·MMedical University of Warsaw·Phase 4·NCT02931045·60 enrolled

Percutaneous Coronary Intervention (PCI)3 trials

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00059215·905 enrolled

Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)

Completed·UUniversity of Patras·Phase 4·NCT01463150·27 enrolled

Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)

Unknown status·UUniversity of Roma La Sapienza·Phase 3·NCT00751491·60 enrolled

Stent Implantation2 trials

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Terminated·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT02494284·364 enrolled

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Completed·EECRI bv·Phase 3·NCT01813435·15,991 enrolled

Fasting Conditions2 trials

Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions

Completed·—·Phase 1·NCT01621750·68 enrolled

Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions

Completed·—·Phase 1·NCT01506713·53 enrolled

Trial2 trials

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Active, not recruiting·RRigshospitalet, Denmark·N/A·NCT06449469·352 enrolled

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II

Completed·—·Phase 4·NCT00130039·457 enrolled

Platelet Inhibition2 trials

Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27

Completed·LLes Laboratoires des Médicaments Stériles·Phase 4·NCT01509365·116 enrolled

Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis

Completed·UUppsala University·Phase 2·NCT00914368·450 enrolled

Diabetes Mellitus2 trials

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00642174·35 enrolled

Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study

Completed·SSeoul National University Bundang Hospital·Phase 3·NCT02294643·220 enrolled

Platelet Function2 trials

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

Completed·TTufts Medical Center·Phase 4·NCT01789814·24 enrolled

Platelet Function Assessment for Atherothrombotic Patients

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT00513149·150 enrolled

P2Y12 Inhibitor2 trials

Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure.

Unknown status·—·Phase 4·NCT03103685·428 enrolled

P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

Terminated·SSamsung Medical Center·Phase 4·NCT03119012·25 enrolled

Thrombosis2 trials

CV004-007 Thrombosis Chamber Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02439190·42 enrolled

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

Completed·AAccumetrics, Inc.·N/A·NCT00645918·2,800 enrolled

Peripheral Arterial Disease2 trials

The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD)

Completed·AArteriogenesis Competence Network·Phase 4·NCT00189618·250 enrolled

CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease

Completed· Sanofi logo

Sanofi·Phase 3·NCT00174759·1,460 enrolled

Transient Ischemic Attack2 trials

Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease

Unknown status· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.··NCT02953405·1,000 enrolled

Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT02975076·120 enrolled

Cerebrovascular Event2 trials

Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events

Completed·—·Phase 3·NCT00979589·5,100 enrolled

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Recruiting·TTianjin Institute of Pharmaceutical Research Co., Ltd·Phase 2·NCT06601127·600 enrolled

Atorvastatin2 trials

Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity

Completed·OOspedale Misericordia e Dolce·Phase 4·NCT01335048·50 enrolled

Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting

Unknown status·—·Phase 4·NCT01572623·150 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Low-dose Ticagrelor

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT03381742·3,043 enrolled

Efficacy and Safety Study of Ticagrelor

Unknown status·GGeneral Hospital of Chinese Armed Police Forces·Phase 3·NCT01812330·180 enrolled

Thrombolysis2 trials

Ticagrelor for PCI Post Thrombolysis

Completed·UUnity Health Toronto·Phase 3·NCT01930591·140 enrolled

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

Withdrawn·—·Phase 4·NCT02048085

Heart Transplantation1 trial

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Recruiting·OOttawa Heart Institute Research Corporation·Phase 3·NCT04770012·135 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 3·NCT02415803·75 enrolled

Atherosclerotic Plaque1 trial

Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation

Completed·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT01905566·50 enrolled

Ischemia1 trial

Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

Terminated·TThe Cleveland Clinic·Phase 2/3·NCT02230527·46 enrolled

Intraoperative1 trial

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel

Unknown status·YYongjian Wu·Phase 4·NCT02513004·60 enrolled

Elderly1 trial

The Elderly ACS II Trial

Completed·AAzienda USL Reggio Emilia - IRCCS·Phase 4·NCT01777503·1,457 enrolled

Completed·UUniversity of Patras·Phase 3·NCT01155765·70 enrolled

Chronic Total Occlusion1 trial

TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization

Completed·HHospital Clinic of Barcelona·Phase 4·NCT02211066·59 enrolled

Vascular Disease1 trial

Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events

Unknown status·—·Phase 3·NCT00775762·213 enrolled

Heart Attack1 trial

Which Therapy for Acute Heart Attacks? (The WEST Study)

Completed·UUniversity of Alberta·Phase 2/3·NCT00121446·300 enrolled

Antithrombotic Agents1 trial

OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT01955200·1,724 enrolled

Necrosis1 trial

ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"

Completed· Sanofi logo

Sanofi·Phase 2·NCT00360386·110 enrolled

ST Elevation Myocardial Infarction1 trial

Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis

Completed·HHospital do Coracao·Phase 3·NCT02298088·3,799 enrolled

Major Cardiovascular Event1 trial

Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg

Completed·LLaboratoires Teriak·Phase 4·NCT03329261·167 enrolled

Microcirculation1 trial

Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers

Completed·UUniversity Hospital, Angers··NCT00152724·85 enrolled

Type 1 Diabetes1 trial

Retinal Blood Flow and Microthrombi in Type 1 Diabetes

Completed·—·Phase 2·NCT00406991·100 enrolled

Preconditioning1 trial

Ticagrelor in Remote Ischemic Preconditioning Study

Completed·HHellenic Society of Interventional Cardiology·Phase 4·NCT04174261·245 enrolled

Endothelial Function1 trial

Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

Unknown status·—·Phase 4·NCT02123004·350 enrolled

Atherosclerosis1 trial

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting·TTongji Hospital··NCT04847752·1,000 enrolled

Staphylococcus Aureus Bacteremia1 trial

Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia

Not yet recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2·NCT07384702·230 enrolled

Infiltration1 trial

Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 4·NCT02639143·50 enrolled

Genetic Polymorphism1 trial

The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers

Completed·IInje University·N/A·NCT01482117·28 enrolled

Miscarriage1 trial

Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages

Unknown status·—·Phase 2/3·NCT01635426·32 enrolled

Immune Response1 trial

The Antiplatelet and Immune Response Trial

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT01846559·30 enrolled

Chronic Kidney Disease1 trial

Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT01768637·48 enrolled

Cardiac Arrest1 trial

Antiplatelet Therapy After Cardiac Arrest

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT02224274·57 enrolled

Idiopathic Pulmonary Arterial Hypertension1 trial

A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension

Completed·—·Phase 2·NCT00105209·20 enrolled

High Bleeding Risk1 trial

Clopidogrel Monotherapy in Patients With High Bleeding Risk

Completed·MMayo Clinic·Phase 4·NCT05223335·98 enrolled

Inflammation1 trial

The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation

Withdrawn·—·Phase 4·NCT02626169

Cerebral Small Vessel Disease1 trial

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University··NCT06715007·300 enrolled

Treatment1 trial

Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

Completed·SStiftung Institut fuer Herzinfarktforschung·Phase 3·NCT01327534·63 enrolled

Antiretroviral Treatment1 trial

Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

Terminated·JJules Desmeules·Phase 1·NCT03054207·21 enrolled

Endotoxemia1 trial

Ticagrelor in Human Endotoxemia Response to Human Endotoxemia

Completed·RRadboud University Medical Center·N/A·NCT02612480·40 enrolled

Ventricular Function1 trial

A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study

Completed·HHellenic Cardiovascular Research Society·Phase 3·NCT02429271·336 enrolled

Complication1 trial

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

Single Antiplatelet Therapy1 trial

Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

Unknown status·FFu Wai Hospital, Beijing, China·Phase 4·NCT06088433·292 enrolled

ART1 trial

Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

Terminated·—·Phase 4·NCT02071966·55 enrolled

Headache1 trial

Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects

Completed·LLaval University·Phase 4·NCT00799045·220 enrolled

Pancreatic Adenocarcinoma1 trial

Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02404363·39 enrolled

Pregnancy1 trial

Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI

Unknown status·—·Phase 4·NCT02696330·150 enrolled

Transcatheter Aortic Valve Replacement1 trial

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Terminated· Bayer logo

Bayer·Phase 3·NCT02556203·1,653 enrolled

Renal artery stenosis1 trial

Zainidip in Renal Artery Stenosis

Completed·LLee's Pharmaceutical Limited·Phase 4·NCT02594410·149 enrolled

Unspecified6 trials

A Pharmacodynamic Study With Ticagrelor in African American Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01523392·50 enrolled

TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement

Completed·UUniversity Hospital, Toulouse·Phase 4·NCT02505399·180 enrolled

A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01523366·53 enrolled

Show 3 more trials

Safety of High-dose Tirofiban During Coronary Angioplasty

Completed·—·Phase 4·NCT00566891·2,000 enrolled

Simplified Anti-Thrombotic Therapy for FFR

Completed·OOdessa Heart Institute·N/A·NCT02384070·300 enrolled

The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT04501900·2,106 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 17, 1997

PLAVIX

NDA NDA020839

Nov 17, 1997

PLAVIX

NDA NDA020839

May 21, 1998

PLAVIX

NDA NDA020839

Aug 20, 1999

PLAVIX

NDA NDA020839

Jan 27, 2000

PLAVIX

NDA NDA020839

Feb 22, 2000

PLAVIX

NDA NDA020839

Mar 15, 2000

PLAVIX

NDA NDA020839

Apr 28, 2000

PLAVIX

NDA NDA020839

Jul 10, 2000

PLAVIX

NDA NDA020839

Jul 25, 2000

PLAVIX

NDA NDA020839

Oct 24, 2000

PLAVIX

NDA NDA020839

Nov 9, 2000

PLAVIX

NDA NDA020839

Mar 7, 2001

PLAVIX

NDA NDA020839

Mar 7, 2001

PLAVIX

NDA NDA020839

Jun 18, 2001

PLAVIX

NDA NDA020839

Jul 19, 2001

PLAVIX

NDA NDA020839

Dec 5, 2001

PLAVIX

NDA NDA020839

Jan 28, 2002

PLAVIX

NDA NDA020839

Feb 27, 2002

PLAVIX

NDA NDA020839

Jun 10, 2002

PLAVIX

NDA NDA020839

Sep 10, 2002

PLAVIX

NDA NDA020839

Sep 29, 2003

PLAVIX

NDA NDA020839

Sep 29, 2003

PLAVIX

NDA NDA020839

Oct 13, 2004

PLAVIX

NDA NDA020839

Apr 25, 2005

PLAVIX

NDA NDA020839

Apr 25, 2005

PLAVIX

NDA NDA020839

Apr 26, 2005

PLAVIX

NDA NDA020839

Oct 14, 2005

PLAVIX

NDA NDA020839

Aug 4, 2006

PLAVIX

NDA NDA020839

Aug 17, 2006

PLAVIX

NDA NDA020839

May 1, 2007

PLAVIX

NDA NDA020839

Sep 20, 2007

PLAVIX

NDA NDA020839

Oct 22, 2007

PLAVIX

NDA NDA020839

May 5, 2009

PLAVIX

NDA NDA020839

Nov 12, 2009

PLAVIX

NDA NDA020839

Mar 12, 2010

PLAVIX

NDA NDA020839

Aug 24, 2010

PLAVIX

NDA NDA020839

Feb 1, 2011

PLAVIX

NDA NDA020839

May 3, 2011

PLAVIX

NDA NDA020839

May 6, 2011

PLAVIX

NDA NDA020839

Dec 20, 2011

PLAVIX

NDA NDA020839

May 24, 2013

PLAVIX

NDA NDA020839

Sep 12, 2013

PLAVIX

NDA NDA020839

Dec 12, 2013

PLAVIX

NDA NDA020839

Mar 12, 2014

PLAVIX

NDA NDA020839

May 14, 2014

PLAVIX

NDA NDA020839

Jul 16, 2015

PLAVIX

NDA NDA020839

Mar 24, 2016

PLAVIX

NDA NDA020839

Sep 16, 2016

PLAVIX

NDA NDA020839

Sep 16, 2016

PLAVIX

NDA NDA020839

Jul 10, 2017

PLAVIX

NDA NDA020839

Oct 31, 2017

PLAVIX

NDA NDA020839

May 25, 2018

PLAVIX

NDA NDA020839

Oct 11, 2018

PLAVIX

NDA NDA020839

May 17, 2019

PLAVIX

NDA NDA020839

Mar 1, 2021

PLAVIX

NDA NDA020839

Sep 16, 2022

PLAVIX

NDA NDA020839

Sep 12, 2023

PLAVIX

NDA NDA020839

Sources

References

[1]
ClinicalTrials.gov — 482 trial records for clopidogrel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Plavix drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — clopidogrel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for clopidogrel. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020839). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Purinergic Receptor P2Y12 Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sanofi

Plavix

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q4 2028

Q1 2029

Trials by Indication[1]

Clopidogrel31 trials

Acute Coronary Syndrome17 trials

Stroke9 trials

Coronary Artery Disease6 trials

Platelet Reactivity6 trials

Antiplatelet6 trials

Myocardial Infarction6 trials

Percutaneous Coronary Intervention5 trials

Antiplatelet Therapy5 trials

Atrial Fibrillation4 trials

Interaction4 trials

Coronary Artery Bypass4 trials

Ischemic stroke4 trials

Antithrombotic3 trials

Dual Antiplatelet Therapy3 trials

Peripheral Artery Disease3 trials

Acute Myocardial Infarction3 trials

Percutaneous Coronary Intervention (PCI)3 trials

Stent Implantation2 trials

Fasting Conditions2 trials

Trial2 trials

Platelet Inhibition2 trials

Diabetes Mellitus2 trials

Platelet Function2 trials

P2Y12 Inhibitor2 trials

Thrombosis2 trials

Peripheral Arterial Disease2 trials

Transient Ischemic Attack2 trials

Cerebrovascular Event2 trials

Atorvastatin2 trials

Efficacy and Safety2 trials

Thrombolysis2 trials

Heart Transplantation1 trial

Safety and Efficacy1 trial

Atherosclerotic Plaque1 trial

Ischemia1 trial

Intraoperative1 trial

Elderly1 trial

Randomized Controlled Trial1 trial

Tics1 trial

Hemodialysis1 trial

Chronic Total Occlusion1 trial

Vascular Disease1 trial

Heart Attack1 trial

Antithrombotic Agents1 trial

Necrosis1 trial

ST Elevation Myocardial Infarction1 trial

Major Cardiovascular Event1 trial

Microcirculation1 trial

Type 1 Diabetes1 trial

Preconditioning1 trial

Endothelial Function1 trial

Atherosclerosis1 trial

Staphylococcus Aureus Bacteremia1 trial

Infiltration1 trial

Genetic Polymorphism1 trial

Miscarriage1 trial

Immune Response1 trial

Chronic Kidney Disease1 trial

Cardiac Arrest1 trial

Idiopathic Pulmonary Arterial Hypertension1 trial

High Bleeding Risk1 trial

Inflammation1 trial

Cerebral Small Vessel Disease1 trial

Treatment1 trial

Antiretroviral Treatment1 trial

Endotoxemia1 trial

Ventricular Function1 trial

Complication1 trial

Single Antiplatelet Therapy1 trial

ART1 trial